Ownership history in 2Xideas AG · 15 quarters on record
This page tracks every 13F SEC filing in which 2Xideas AG reported a position in HALOZYME THERAPEUTICS INC (HALO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 104,801 | -54,023 | -34.0% | 1.98% | $7.1M | $67.30 |
| 2025 Q3 | REDUCED | 158,824 | -25,722 | -13.9% | 2.46% | $11.6M | $73.34 |
| 2025 Q2 | REDUCED | 184,546 | -62,256 | -25.2% | 1.65% | $9.6M | $52.02 |
| 2025 Q1 | REDUCED | 246,802 | -132,438 | -34.9% | 2.39% | $15.7M | $63.81 |
| 2024 Q4 | ADDED | 379,240 | +73,653 | +24.1% | 2.43% | $18.1M | $47.81 |
| 2024 Q3 | REDUCED | 305,587 | -193,370 | -38.8% | 2.36% | $17.5M | $57.24 |
| 2024 Q2 | REDUCED | 498,957 | -16,505 | -3.2% | 3.26% | $26.1M | $52.36 |
| 2024 Q1 | REDUCED | 515,462 | -28,704 | -5.3% | 2.60% | $21.0M | $40.68 |
| 2023 Q4 | REDUCED | 544,166 | -56,633 | -9.4% | 2.16% | $20.1M | $36.96 |
| 2023 Q3 | REDUCED | 600,799 | -44,489 | -6.9% | 2.51% | $23.0M | $38.20 |
As of 2025 Q4 — sorted by position size